Next Article in Journal
Discovering Rare Genes Contributing to Cancer Stemness and Invasive Potential by GBM Single-Cell Transcriptional Analysis
Next Article in Special Issue
Pain Management in Patients with Multiple Myeloma: An Update
Previous Article in Journal
Identification of a Subtype of Hepatocellular Carcinoma with Poor Prognosis Based on Expression of Genes within the Glucose Metabolic Pathway
Previous Article in Special Issue
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Review

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Suita, 1-7 Yamada-Oka, Suita, Osaka 565-0871, Japan
Cancers 2019, 11(12), 2024; https://doi.org/10.3390/cancers11122024
Received: 11 November 2019 / Revised: 12 December 2019 / Accepted: 13 December 2019 / Published: 15 December 2019
(This article belongs to the Special Issue Latest Development in Multiple Myeloma)
CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma. Many researchers are now trying to develop CAR T cells for various types of cancer. For multiple myeloma (MM), B-cell maturation antigen (BCMA) has been recently proved to be a promising target. However, cure of MM is still difficult, and several other targets, for example immunoglobulin kappa chain, SLAM Family Member 7 (SLAMF7), or G-protein coupled receptor family C group 5 member D (GPRC5D), are being tested as targets for CAR T cells. We also reported that the activated integrin β7 can serve as a specific target for CAR T cells against MM, and are preparing a clinical trial. In this review, we summarized current status of CAR T cell therapy for MM and discussed about the future perspectives. View Full-Text
Keywords: CAR T cell; immunotherapy; multiple myeloma; integrin CAR T cell; immunotherapy; multiple myeloma; integrin
Show Figures

Figure 1

MDPI and ACS Style

Hosen, N. Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. Cancers 2019, 11, 2024. https://doi.org/10.3390/cancers11122024

AMA Style

Hosen N. Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. Cancers. 2019; 11(12):2024. https://doi.org/10.3390/cancers11122024

Chicago/Turabian Style

Hosen, Naoki. 2019. "Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma" Cancers 11, no. 12: 2024. https://doi.org/10.3390/cancers11122024

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop